Regeneron Pharmaceuticals (NasdaqGS:REGN) Drops 10% Over Last Week Despite Dupixent Approval in Japan
The Investor’s View on Regeneron Pharmaceuticals Is Regeneron Pharmaceuticals a buy, hold, or sell in 2023? As investors, we constantly analyze financial health, potential growth, and industry positioning. Recent data shows that Regeneron has delivered a total shareholder return of 11.94% over the last five years, a strong performance in the biopharma sector. Investors are … Read more